Work

Abstract PS2-11-13: Resistance to tucatinib associated with hyperactive EGFR could be overcome by co-targeting HER2 and EGFR in HER2-positive breast cancer models

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps2-11-13

Authors: F. Liao, L. Qin, S. Nanda, M. J. Shea, C. Liu, C. M. Sabotta, A. Elkhanany, S. G. Hilsenbeck, C. Gutierrez, M. F. Rimawi, C. K. Osborne, J. Veeraraghavan, R. Schiff

Institutions: Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129757476

Cites:

Cited by:

Related to: